NORD ANGLIA ED Stock Price, News & Analysis

Orocidin, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced positive efficacy results for its lead periodontitis treatment candidate, QR-01, in a preclinical study with dogs. The 13-day small efficacy study, conducted on beagle dogs with clinically confirmed periodontitis, showed consistent improvements across key clinical endpoints including:

• Gingival Index
• Plaque Index
• Overall periodontal Disease

The treatment was well-tolerated with no adverse side effects reported. The company plans to proceed with a human pilot efficacy study scheduled to begin by the end of 2025.

Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced a strategic partnership with Syngene International . The collaboration aims to advance GMP peptide development programs using cutting-edge technology and scalable solutions.

The partnership will focus on developing Orocidin's QR-01, leveraging Syngene's capabilities in efficient and scalable manufacturing with reduced lead times. Syngene's infrastructure will provide access to skilled scientists and state-of-the-art facilities, ensuring a robust and streamlined supply chain for future commercialization.

This strategic alliance aligns with Nordicus Partners' specialization in supporting Nordic and U.S. life sciences companies establishing themselves in the U.S. market.

Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis. The study involved dosing hamsters over a 2-week period with concentrations 5-8 times higher than planned for the upcoming pilot efficacy study in patients.

The results demonstrated high drug tolerance in all test subjects, with no adverse reactions or irritation at the buccal application site. Notably, necroscopic cross examination revealed no tissue changes. This successful completion marks a significant milestone for Orocidin, paving the way for the upcoming pivotal eight-week toxicity study.

Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has developed QR-02, a novel oral topical treatment for oral leukoplakia with moderate to severe dysplasia. The treatment addresses a significant market of 15.5 million patients in the U.S. and EU, where 10-30% of cases may develop into oral cancer.

QR-02's key innovation is its mucoadhesive formulation that adheres to the oral cavity for 12-24 hours, compared to traditional treatments lasting only 15-20 minutes. The treatment uses imiquimod, an FDA-approved active ingredient, in a unique oral application format. The product aims to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.

Orocidin A/S, a subsidiary of Nordicus Partners (NORD), has introduced a breakthrough dental gel for long-term periodontitis treatment. The innovative low-viscosity gel features a unique active peptide and is designed for direct application into dental pockets by dentists using a syringe and flushing cannula.

The gel's key innovation lies in its formulation of triglycerides, monoglycerides, and water. Upon contact with oral cavity moisture, it forms a semi-solid bioadhesive crystalline matrix, enabling slow and localized release of the active ingredient. All components are biocompatible and FDA-approved for oral use.

Nordicus Partners (NORD) announced that its subsidiary, Orocidin A/S, will begin its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to be completed by Q3 2025, enabling the launch of the first pilot efficacy study in patients by year-end.

Orocidin is a proprietary treatment for periodontitis that addresses three key challenges: inflammation reduction, bacterial infection elimination, and bone/teeth regeneration. The company has filed patent applications to protect the product's innovative design.

The development represents a significant milestone in bringing this dental health solution to market, targeting an unmet medical need.

Nordicus Partners (OTCQB:NORD) has announced that its wholly-owned subsidiaries, Orocidin A/S and Bio-Convert ApS, plan to initiate pilot efficacy studies in 2025. These studies will focus on patients with periodontitis and oral leukoplakia. The company clarified that both subsidiaries are currently in the preclinical phase, correcting information provided in previous press releases.

Nordicus Partners (OTCQB:NORD) announced that FINRA has removed the appending 'D' from its OTC equity symbol following the completion of a 20-day transition period related to its previously announced reverse split. The company's common stock will continue trading on the OTCQB market under the symbol 'NORD' starting December 9, 2024. The new CUSIP number following the reverse stock split is 28265K 304. Nordicus is a financial consulting company that specializes in helping Nordic and U.S. life sciences companies establish themselves in the U.S. market.

Nordicus Partners (OTCQB: NORD) has announced the acquisition of the remaining 5% shares in Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company focused on periodontitis treatment. The transaction involves 200,000 restricted common shares of Nordicus in exchange for the outstanding Orocidin shares, making Orocidin a 100% wholly-owned subsidiary of Nordicus. The deal strengthens Nordicus's position in facilitating Nordic and U.S. life sciences companies' establishment in the U.S. market.